Ten Past Years United · One New Horizon Arises

To all colleagues, partners, and friends of Canton Biologics,

As we stand at the end of this year and look back, we see time moving forward—quietly yet steadfastly. Much of today’s weariness, hesitation, or uncertainty may fade from memory, but one thing will remain: amid unpredictability, we chose to plan thoughtfully, build consistently, and prepare for new beginnings.

Looking back over the past decade, I have grown increasingly convinced that the world is shifting—from a sole focus on efficiency toward a greater emphasis on safety, resilience, and longterm value. Geopolitics, technology governance, industrial restructuring, and capital cycles intertwine, reminding us of a simple yet profound truth: what truly matters often requires time, patience, and the systematic accumulation of capability.

This is the backdrop against which Canton Biologics’ story unfolds.

Ten years ago, we set out from Guangzhou with a business plan that was far from perfect—one that could easily have been dismissed. Starting from a technical foundation, we began this journey without knowing exactly how a biotech company should grow, or whether our first round of funding would ever come. Yet from that very moment, Canton Biologics took its first step.

Every phase since has demanded perseverance.

Amid the rapid expansion of China’s macromolecular CDMO sector, we committed to building a GMP production system in South China with longterm competitiveness. Despite global pandemic disruptions and sudden shifts in financing, we chose to go global—acquiring and reinventing Germany’s FyoniBio to gradually establish a foundational biologics manufacturing platform with worldwide reach. Through setbacks and adjustments, we learned to focus more deeply on work that carries real technological weight and stands the test of time.

Today, Canton Biologics has built an integrated facility network spanning R&D to commercialscale production:

    · In Germany, our FyoniBio CDO center focuses on earlystage biologics development and underlying technology innovation.

    · In China, we operate a ~3,600 m² CDO R&D center in Guangzhou, alongside GMP production bases of ~14,000 m² in Guangzhou and ~12,000 m² in       
       Foshan. Together they cover a full range from 50 L to 2,000 L for drug substance, formulation, perfusion, and cell & virusrelated production needs.

This Sino-German multisite system enables us to deliver end-to-end solutions to global clients—from discovery through commercialization.

What matters even more, however, are the people.

Today, Canton Biologics brings together scientists, engineers, and industrialization experts from around the world. Our team now exceeds 300 members. We do not pursue growth that merely “looks fast”; instead, we aim for every step to be reliable, verifiable, and sustainable.

Looking back from where we stand now, I see more clearly than ever:

Canton Biologics is no longer just a plan, nor an idealized experiment. It is an ongoing industrial practice—one that will ultimately be recorded. Perhaps we have not always been “growing bigger,” but we have always been “growing stronger.”

The next decade will still be full of challenges.

We will continue to attract outstanding scientists and engineers, refining our technology platforms.

We will bring R&D achievements from China, from Canton Biologics, to international academic and industry stages.

Together with clients and partners, we will translate innovation into accessible, affordable, and sustainable healthcare solutions.

And we will keep building higherstandard automated facilities to serve both China and the world.

None of this is any one person’s plan. It is a story being written by many.

Each year is a chapter; every ten years, a volume.

The second volume of The Canton Biologics Series is now unfolding.

Thank you for your trust and perseverance.

Let us continue forward—together, steadily.